Sei Investments Co. Invests $303,000 in Akero Therapeutics, Inc. (NASDAQ:AKRO)

Sei Investments Co. acquired a new position in Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 10,887 shares of the company's stock, valued at approximately $303,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. AlphaQuest LLC grew its stake in Akero Therapeutics by 32,588.0% during the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after purchasing an additional 8,147 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Akero Therapeutics in the 3rd quarter valued at about $308,000. Proficio Capital Partners LLC purchased a new stake in shares of Akero Therapeutics during the fourth quarter worth approximately $320,000. Teacher Retirement System of Texas grew its holdings in Akero Therapeutics by 18.7% during the 4th quarter. Teacher Retirement System of Texas now owns 14,415 shares of the company's stock worth $401,000 after acquiring an additional 2,274 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of Akero Therapeutics by 10.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,800 shares of the company's stock valued at $412,000 after purchasing an additional 1,446 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have commented on AKRO shares. Bank of America upgraded shares of Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. UBS Group boosted their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research report on Friday, January 31st. HC Wainwright lifted their target price on Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Citigroup boosted their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Finally, Morgan Stanley reissued an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $76.29.

Remove Ads

Akero Therapeutics Trading Down 2.9 %

Shares of AKRO stock traded down $1.11 during trading hours on Wednesday, reaching $36.97. 47,480 shares of the stock traded hands, compared to its average volume of 854,515. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $2.94 billion, a PE ratio of -9.91 and a beta of -0.18. Akero Therapeutics, Inc. has a 1-year low of $17.86 and a 1-year high of $58.40. The business has a fifty day moving average price of $44.12 and a 200 day moving average price of $35.99.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). On average, equities research analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Insider Transactions at Akero Therapeutics

In other news, CEO Andrew Cheng sold 30,000 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $54.90, for a total value of $1,647,000.00. Following the sale, the chief executive officer now directly owns 716,062 shares in the company, valued at approximately $39,311,803.80. This represents a 4.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO William Richard White sold 676 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $44.88, for a total value of $30,338.88. Following the transaction, the chief financial officer now owns 61,959 shares of the company's stock, valued at $2,780,719.92. This represents a 1.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders purchased 341,309 shares of company stock worth $15,863,578 and sold 278,385 shares worth $13,345,929. 7.94% of the stock is currently owned by corporate insiders.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.